QMatter secures £900k pre-seed for quantum compression to shrink drug discovery simulations
This article covers QMatter, a biotech startup that has raised £900k in a pre-seed funding round to develop and scale a "quantum compression" platform to shrink complex computational problems so they can be run on current quantum and classical hardware. The development aims to support pharmaceutical and biotechnology research by speeding simulations used in drug discovery and materials research and making larger quantum-mechanical problems tractable on today’s hardware.
QMatter, a biotech startup, has raised £900,000 in a pre-seed funding round to develop and scale a “quantum compression” platform designed to shrink complex computational problems so they can be run on current quantum and classical hardware. The round backs a team that says the technology could speed simulations used in drug discovery and materials research, where computational limits are a key barrier.
Why it matters
Simulating quantum mechanics at scale remains one of the hardest computational problems in science. That constraint limits how quickly researchers can explore new molecules, materials and therapeutic candidates. QMatter’s approach aims to reduce problem size before simulation, which could make more ambitious calculations tractable on today’s machines and improve throughput for both quantum and classical workflows.
If the compression preserves the physics that matter for a given task, it could reduce hardware needs and shorten times to insight for pharma and biotech research teams. That combination is why early-stage interest is emerging at the intersection of quantum computing and life sciences.
Inside the product
QMatter applies principles from quantum mechanics to identify and retain the essential core of a computational problem. The company says this both extends the capability of near-term quantum devices and can accelerate classical algorithms across systems ranging from consumer hardware to supercomputers.
The startup is focused on the life sciences market, working with pharmaceutical and biotechnology companies to improve simulation output and speed up research and development. In parallel, QMatter is creating physics-informed data libraries intended to help machine learning companies train models on problem-specific datasets.
QMatter was founded in 2024 by Dr Alexis Ralli and Dr Timothy Weaving, alongside Professor Peter Coveney and Professor Peter Love. The founding team brings experience in quantum computing and high-performance computing with an explicit focus on life science applications. The new funding will be used to further develop and scale the quantum compression platform.
In the announcement, Alexis Ralli, Co-founder & CEO at QMatter, said:
QMatter compresses complex quantum problems to their essential core, ensuring solutions remain both accurate and useful. By doing so, we unlock greater performance from today's quantum hardware while broadening the problem landscape for future error-corrected machines.
In the announcement, Timothy Weaving, Co-founder & CTO at QMatter, said:
Quantum computing promises to be transformational for the hardest problems we face, but the full value remains unrealized due to real-world limitations that constrain the size of problems we can address today. This investment will support the continued development of our quantum compression platform.
Who are the investors?
The round was led by 55 North, with participation from XTX Ventures, Bellstate Oy and the Conception X Angel Syndicate. Conception X is an angel syndicate; the other participants are listed in the announcement as co-investors.
In the announcement, Helmut Katzgraber, Partner at 55 North, said:
The first commercially valuable applications of quantum computing devices will likely be in chemistry and pharmaceuticals. QMatter’s compression approach accelerates the timelines and brings these applications closer to the market.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
The founders position the technology as an enabler rather than a replacement for existing compute. Their stated aim is to make larger, more realistic scientific problems accessible to current hardware and to prepare workflows for future error-corrected quantum machines. The team mixes academic expertise with engineering focused on applied life science use cases.
The bigger picture
QMatter’s raise is one of several early-stage bets tying quantum research to practical life science problems. The deal reflects ongoing appetite from biotech investors for tools that can materially speed lab workflows and improve simulation fidelity, even before large-scale fault-tolerant quantum computers arrive.
As quantum hardware improves, software techniques that reduce problem size or improve data for machine learning will play an important role in whether quantum advantage translates into commercial impact. Early UK and European funding for companies like QMatter helps bridge academic research and industry use cases, keeping the region competitive in quantum-enabled life science innovation.
They've invested in QMatter
Get to know these biotech investors
Click here for a full list of 7,589+ startup investors in the UK